Israeli medtech startup Bonus Biogroup, which developed a way to grow tissue from your own body in vitro in order to replace lost bone, has announced a complete success in 90 percent of the 30 patients in a Phase 2 trial for treating facial bone deficiencies.
The trial was based on the company’s proprietary BonoFill platform, which grows cells from the body according to the needs of the individual patient.
Bonus Biogroup defines success as achieving a natural and complete jawbone six months after transplantation. But, the company said, it took just three months for 87 percent of the patients who underwent a transplant to have completely healed and regenerated bone to the maximum levels.
“Publishing these Phase II results is a milestone of global achievement for us,” said Bonus Biogroup CEO Dr. Shai Meretzki.
“As a company dedicated to turning the promise of tissue engineering into practical bone restoration, we have taken a significant step towards making BonoFill a unique solution for millions of patients,” he said.
“The results of the Phase II trial indicate a significant, potential breakthrough in the treatment of facial bone deficiencies,” said Dr. Ephraim Tzur, an expert in oral and maxillofacial surgery who led the clinical trial.
“The patients in the trial experienced rapid healing of large and complex deficiencies without significant complications that frequently arise with standard treatment. The bone built using BonoFill is stronger and is expected to support better rehabilitative procedures.”
Facebook comments